Ombitasvir; paritaprevir; ritonavir - Generic Drug Details

What are the generic drug sources for ombitasvir; paritaprevir; ritonavir and what is the scope of freedom to operate?

Ombitasvir; paritaprevir; ritonavir is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ombitasvir; paritaprevir; ritonavir has four hundred and forty-nine patent family members in forty-eight countries.

Summary for ombitasvir; paritaprevir; ritonavir

International Patents:	449
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	41
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ombitasvir; paritaprevir; ritonavir
DailyMed Link:	ombitasvir; paritaprevir; ritonavir at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ombitasvir; paritaprevir; ritonavir

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ombitasvir; paritaprevir; ritonavir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Phase 4
South Valley University	Phase 4
Sohag University	Phase 4

See all ombitasvir; paritaprevir; ritonavir clinical trials

US Patents and Regulatory Information for ombitasvir; paritaprevir; ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No			Y	Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No					Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No

Expired US Patents for ombitasvir; paritaprevir; ritonavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015

EU/EMA Drug Approvals for ombitasvir; paritaprevir; ritonavir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Viekirax	ombitasvir, paritaprevir, ritonavir	EMEA/H/C/003839 Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.	Authorised	no	no	no	2015-01-14

International Patents for ombitasvir; paritaprevir; ritonavir

Country	Patent Number	Title	Estimated Expiration
Portugal	2692346
European Patent Office	2692346	Dérivé antiviraux de 2,5-dibenzimidazol-5-yl-1-phényl-pyrrolidine (An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative)
Chile	2011000512	(2r,6s,13as,14ar,16as,z)-n- (ciclopropilsulfonil)-6-(5-metilpirazin-2-carboxamido)-5,16-dioxo-2-(fenantridin-6-iloxi)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahidrociclopropa[e]pirrolo[1,2-a][1,4]diazaciclopentadecin-14a-carboxamida y composicion farmaceutica que lo comprende.
Chile	2012003470	Una composicion solida que comprende 1) un compuesto inhibidor del hcv de formula definida, o una sal farmaceuticamente aceptable de este, en una forma amorfa, 2) un polimero hidrofilico, y opcionalmente 3) un agente tensoactivo; su proceso de preparacion, util para tratar una infeccion del hcv.
Israel	185390	צורת מינון רוקחית מוצקה (Solid pharmaceutical dosage formulation)

Supplementary Protection Certificates for ombitasvir; paritaprevir; ritonavir

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2340029	C20150019 00156	Estonia		PRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
2692346	C20170036 00243	Estonia		PRODUCT NAME: PIBRENTASVIIR;REG NO/DATE: EU/1/17/1213 28.07.2017
2692346	299 50017-2017	Slovakia		PRODUCT NAME: PIBRENTASVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728
2340029	599	Finland
2340029	C02340029/01	Switzerland		PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014